Phaseline

Targets › RPSA

RPSA (Small ribosomal subunit protein uS2): drug programs, companies and trials

2 programs from 2 companies in 2 trials: 1 Phase 2, 1 Phase 1; Other, Oncology; next expected readout Jun 2027.

Required for the assembly and/or stability of the 40S ribosomal subunit. Required for the processing of the 20S rRNA-precursor to mature 18S rRNA in a late step of the maturation of 40S ribosomal subunits. (UniProt, P08865)

Open in Phaseline: the race on RPSA, likelihood bands and readouts

Programs

CompanyDrugTargetsHighest phaseConditionsNext expected readout
Eloxx PharmaceuticalsElx-02
80S Ribosome modulator
RPSA, RPS27, RPS6, RPS2, RPS3Phase 2Alport Syndrome, X-LinkedJun 2027
Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)Ataluren
80S Ribosome modulator
RPSA, RPS27, RPS6, RPS2, RPS3Phase 1Colorectal Cancer–

Conditions

Alport Syndrome, X-Linked (1) Colorectal Cancer (1)

Modalities

small molecule (1), antibody (1)

Companies

Eloxx Pharmaceuticals (1) Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA) (1)

Related targets

RPS27 (2) RPS6 (2) RPS2 (2) RPS3 (2)

Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.